ValuentumAd

Official PayPal Seal
Valuentum Reports













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Latest Valuentum Commentary

Feb 2, 2016
Early Read: Gilead Guides Revenue to Decline in 2016, Below Consensus
The growth spurt may be over, and we’re most worried about the back half of this decade.
Feb 1, 2016
Google…Ahem…Alphabet!
We’re still getting used to Google’s new name, but its performance is something we certainly can get used to.
Jan 29, 2016
Alerts: High-grading! GILD-->JNJ; EBAY-->FB
We’re “high-grading” the Best Ideas Newsletter portfolio.
Jan 25, 2016
What’s Working in Today’s Market?
Let’s take a look at the major sectors to see where assets are flocking to and away from so far in 2016. We’ll talk about recent news, and several equities we’re paying particularly close attention to for addition to the newsletter portfolios.
Jan 13, 2016
The 20 Something’s Stock Portfolio
Let’s have some fun. There’s nothing dull about this portfolio.
Dec 18, 2015
Analysis: The Best Ideas Portfolio
The Best Ideas Newsletter portfolio is one of the most followed newsletter portfolios among our membership. In the spirit of transparency, let’s examine the portfolio’s returns from a variety of different perspectives. The Best Ideas Newsletter portfolio and Dividend Growth Newsletter portfolio are not real money portfolios. Results are hypothetical and do not represent actual trading. Past results are not a guarantee of future performance.
Dec 6, 2015
Leading Investors to Water…
…did they drink? Let’s examine the performance of Valuentum’s best ideas in 2015.
Oct 28, 2015
Around the Horn in Biotech/Pharma: 3Q Earnings Review
Abbott, Biogen, Bristol-Myers, Eli Lilly, Gilead, GlaxoSmithKline, Merck, Pfizer…
Oct 26, 2015
If It Happened to AbbVie, Could It Also Happen to Gilead?
Recent news concerning AbbVie’s hepatitis C drugs caused a severe decline in the company’s share price. Could such an event happen to Gilead?
Oct 6, 2015
Attention to Pricing Issues Pressures Valeant
Along with the biotech industry as a whole, Valeant Pharmaceuticals has been the subject of negative publicity lately, and its shares have paid the price.


Latest News and Media
The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.